Origin Materials (ORGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 May, 2026Executive summary
The board unanimously approved a plan for complete liquidation and dissolution, subject to stockholder approval, after failing to secure strategic alternatives or financing to continue operations.
Most commercial activities have ceased, and the majority of employees will be terminated by the end of Q2 2026.
The special meeting will be held virtually, with stockholders voting on the dissolution and adjournment proposals.
If approved, the board will oversee asset liquidation, liability settlement, and distribution of proceeds to stockholders.
Estimated initial liquidation distribution is between $0.61 and $3.54 per share, depending on asset sale outcomes and liabilities.
Voting matters and shareholder proposals
Stockholders will vote on: (1) approval of the plan of dissolution and (2) granting the board authority to adjourn the meeting to solicit more proxies if needed.
The board recommends voting FOR both proposals.
Abstentions and failures to vote count as votes against the dissolution proposal.
No other matters are expected, but proxies may vote on additional business if properly brought before the meeting.
Board of directors and corporate governance
The board retains discretion to delay or abandon the dissolution if circumstances change before filing the certificate of dissolution.
After dissolution, most directors are expected to resign, and the board size will be reduced to save costs.
The board may appoint a third party or liquidating trust to manage the wind-down process.
Latest events from Origin Materials
- Stockholders will vote on a proposed dissolution, with estimated payouts of $0.61–$3.48 per share.ORGN
Proxy filing14 May 2026 - Dissolution plan approved, operations winding down, and Q1 revenue fell 91% year-over-year.ORGN
Q1 202614 May 2026 - Breakeven delayed to 2028 as PET cap commercialization progresses amid urgent liquidity needs.ORGN
Q4 202527 Mar 2026 - Stockholders approved a reverse split and major share issuance, advancing strategic milestones.ORGN
EGM 202618 Feb 2026 - $100M+ PET cap deal signed; Q2 loss $19.5M; Q4 2024 production on track.ORGN
Q2 20241 Feb 2026 - Strong PET cap demand, $100M+ MOU, and EBITDA positivity targeted for 1H 2026.ORGN
Q3 202414 Jan 2026 - Rapid transformation to PET caps leverages technical strengths, innovation, and scalable growth.ORGN
Fireside Chat9 Jan 2026 - Key votes on reverse stock split and major share issuance set for February 2026.ORGN
Proxy Filing6 Jan 2026 - Approval sought for reverse split and convertible note share issuance to support listing and funding.ORGN
Proxy Filing6 Jan 2026